$PULM
Pulmatrix, Inc. Stock $pulm

$pulm Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223027468 Filed on August 10, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$1.753M	$1.844M	$1.331M
YoY Change	-6.36%	38.54%	-40.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.730M	$1.670M	$1.553M
YoY Change	2.67%	7.53%	-0.58%
% of Gross Profit
Research & Development	$3.963M	$4.165M	$4.337M
YoY Change	-25.04%	-3.97%	-4.49%
% of Gross Profit
Depreciation & Amortization	$40.00K	$32.00K	$47.00K
YoY Change	-2.44%	-31.91%	23.68%
% of Gross Profit
Operating Expenses	$5.692M	$5.835M	$5.890M
YoY Change	-18.36%	-0.93%	-3.49%
Operating Profit	-$3.939M	-$3.991M	-$4.559M
YoY Change	-22.76%	-12.46%
Interest Expense	$220.0K	$236.0K	$15.00K
YoY Change	115.69%	1473.33%	650.0%
% of Operating Profit
Other Income/Expense, Net	$165.0K	$175.0K	-$51.00K
YoY Change	243.75%	-443.14%	920.0%
Pretax Income	-$3.770M	-$3.816M	-$4.595M
YoY Change	-25.38%	-16.95%	19.29%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$3.774M	-$3.816M	-$4.595M
YoY Change	-25.3%	-16.95%	19.29%
Net Earnings / Revenue	-215.29%	-206.94%	-345.23%
Basic Earnings Per Share	-$1.03	-$1.04	-$1.36
Diluted Earnings Per Share	-$1.03	-$1.04	-$1.363M
COMMON SHARES
Basic Shares Outstanding	3.652M shares	3.652M shares	3.372B shares
Diluted Shares Outstanding	3.652B shares	3.652B shares	3.372B shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.34M	$25.79M	$42.91M
YoY Change	-47.55%	-39.89%	-24.6%
Cash & Equivalents	$21.34M	$25.79M	$42.91M
Short-Term Investments
Other Short-Term Assets	$1.050M	$1.172M	$2.295M
YoY Change	-49.18%	-48.93%	27.5%
Inventory
Prepaid Expenses
Receivables	$841.0K	$418.0K	$645.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$23.23M	$27.38M	$45.85M
YoY Change	-46.26%	-40.27%	-24.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.166M	$279.0K	$1.713M
YoY Change	340.0%	-83.71%	23.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$217.0K	$1.984M	$1.840M
YoY Change	-49.3%	7.83%
Total Long-Term Assets	$13.54M	$4.012M	$3.553M
YoY Change	319.88%	12.92%	-28.42%
TOTAL ASSETS
Total Short-Term Assets	$23.23M	$27.38M	$45.85M
Total Long-Term Assets	$13.54M	$4.012M	$3.553M
Total Assets	$36.77M	$31.39M	$49.40M
YoY Change	-20.84%	-36.45%	-24.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$707.0K	$929.0K	$728.0K
YoY Change	-38.79%	27.61%	-51.72%
Accrued Expenses	$2.520M	$1.465M	$3.312M
YoY Change	-8.3%	-55.77%	39.45%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.429M	$3.597M	$5.601M
YoY Change	-29.97%	-35.78%	-19.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$12.46M	$4.347M	$5.358M
YoY Change	145.28%	-18.87%	-1.2%
Total Long-Term Liabilities	$12.46M	$4.347M	$5.358M
YoY Change	145.28%	-18.87%	-1.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.429M	$3.597M	$5.601M
Total Long-Term Liabilities	$12.46M	$4.347M	$5.358M
Total Liabilities	$16.89M	$7.944M	$10.96M
YoY Change	48.1%	-27.51%	-11.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$285.5M	-$281.7M
YoY Change	6.04%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.88M	$23.45M	$38.44M
YoY Change
Total Liabilities & Shareholders Equity	$36.77M	$31.39M	$49.40M
YoY Change	-20.84%	-36.45%	-24.51%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$3.774M	-$3.816M	-$4.595M
YoY Change	-25.3%	-16.95%	19.29%
Depreciation, Depletion And Amortization	$40.00K	$32.00K	$47.00K
YoY Change	-2.44%	-31.91%	23.68%
Cash From Operating Activities	-$4.140M	-$4.904M	-$4.562M
YoY Change	14.87%	7.5%	-30.02%
INVESTING ACTIVITIES
Capital Expenditures	$310.0K	$58.00K	-$67.00K
YoY Change		-186.57%	272.22%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$310.0K	-$58.00K	-$67.00K
YoY Change		-13.43%	272.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change	-100.0%		-100.0%
NET CHANGE
Cash From Operating Activities	-4.140M	-4.904M	-4.562M
Cash From Investing Activities	-310.0K	-58.00K	-67.00K
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	-4.450M	-4.962M	-4.629M
YoY Change	100.27%	7.19%	-29.16%
FREE CASH FLOW
Cash From Operating Activities	-$4.140M	-$4.904M	-$4.562M
Capital Expenditures	$310.0K	$58.00K	-$67.00K
Free Cash Flow	-$4.450M	-$4.962M	-$4.495M
YoY Change	23.47%	10.39%	-30.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001574235
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q1	PULM	Stock Issued During Period Value Adjustment Due To Reverse Stock Split StockIssuedDuringPeriodValueAdjustmentDueToReverseStockSplit		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	PULM	Proceeds From Issuance Of Preferred Stock And Common Stock Warrants Net Of Issuance Costs ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrantsNetOfIssuanceCosts		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	PULM	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock		usd
	PULM	Fixed Asset Purchases In Accounts Payable FixedAssetPurchasesInAccountsPayable		usd
CY2022Q4	PULM	Accrued Legal And Patent Current AccruedLegalAndPatentCurrent		usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36199
	dei	Entity Registrant Name EntityRegistrantName	PULMATRIX, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1821392
	dei	Entity Address Address Line1 EntityAddressAddressLine1	36 Crosby Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bedford
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01730
	dei	City Area Code CityAreaCode	(781)
	dei	Local Phone Number LocalPhoneNumber	357-2333
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	PULM
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3652285	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25791000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35628000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	153000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	153000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	418000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1298000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1019000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1068000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	27381000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	38147000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	279000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	235000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	277000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	710000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1472000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1472000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1984000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	389000	usd
CY2023Q2	us-gaap	Assets Assets	31393000	usd
CY2022Q4	us-gaap	Assets Assets	40953000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	929000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1188000	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1201000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1638000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	358000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	857000	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1109000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1339000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3597000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5022000	usd
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4347000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4822000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	7944000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	9844000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3652285	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3652285	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3639185	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3639185	shares
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	305189000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	304585000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-281740000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-273476000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	23449000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	31109000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31393000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40953000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1844000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1331000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3343000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2491000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4165000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4337000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8039000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8486000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1670000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1553000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3880000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3527000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3816000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	23449000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	47449000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	281000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	5835000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	5890000	usd
	us-gaap	Operating Expenses OperatingExpenses	11919000	usd
	us-gaap	Operating Expenses OperatingExpenses	12013000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3991000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4559000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8576000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9522000	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	236000	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	15000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	458000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	16000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-61000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-51000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-146000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-62000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	175000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-36000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	312000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-46000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3816000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4595000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8264000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9568000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.04
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.36
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.36
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.87
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.87
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3652285000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3652285000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3372090000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3372090000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3651531000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3651531000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3334891000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3334891000	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	31109000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	53000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	296000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4448000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	27010000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	255000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	42757000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	42757000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4973000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	277000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4595000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	38439000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	38439000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8264000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9568000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	64000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	82000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	777000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	686000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	551000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	558000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-880000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	578000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-49000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1271000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1595000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	368000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-309000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	51000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-437000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	377000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-843000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-586000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-705000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-89000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9832000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10706000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	58000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	77000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-58000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-77000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53000	usd
	PULM	Proceeds From Issuance Of Preferred Stock And Common Stock Warrants Net Of Issuance Costs ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrantsNetOfIssuanceCosts	-152000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-152000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9837000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10935000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37253000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	55465000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27416000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	44530000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25791000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42905000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	153000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	153000	usd
CY2022Q4	PULM	Prepaid Software And Hosting Costs PrepaidSoftwareAndHostingCosts	99000	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	272000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	166000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1019000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1472000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1472000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27416000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	44530000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	344000	usd
	PULM	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	50000	usd
	PULM	Fixed Asset Purchases In Accounts Payable FixedAssetPurchasesInAccountsPayable	1081000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zOSIA6eHjuPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zLhm3A28AHoa">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. The most significant estimates and assumptions in the Company’s condensed consolidated financial statements include, but are not limited to, estimates of future expected costs in order to derive and recognize revenue, estimates related to clinical trial accruals and upfront deposits, incremental borrowing rate, and accounting for income taxes and the related valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zXbHtwTpqjp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zZLpNeB16Qo6">Concentrations of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in accounts at a single financial institution that management believes is creditworthy, and the Company has not incurred any losses to date. The Company is exposed to credit risk in the event of default by this financial institution for amounts in excess of the Federal Deposit Insurance Corporation insured limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and six months ended June 30, 2023, revenue from one customer accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zic2vEkaZS3e" title="Concentration risk percentage"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zkr1K4YuBmi5" title="Concentration risk percentage">100</span></span>% of revenue recognized in the accompanying condensed consolidated financial statements. For the three and six months ended June 30, 2022, revenue from one customer accounted for approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zPIPgYv0T4q6" title="Concentration risk percentage"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z1SMHcH8N0Wa" title="Concentration risk percentage">99</span></span>% of revenue recognized in the accompanying condensed consolidated financial statements. As of June 30, 2023 and December 31, 2022, one customer accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z0PzUDeU46W7" title="Concentration risk percentage"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zJHinv2wYQSe" title="Concentration risk percentage">100</span></span>% of accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	496000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	286000	usd
CY2023Q2	PULM	Prepaid Clinical And Consulting PrepaidClinicalAndConsulting	132000	usd
CY2022Q4	PULM	Prepaid Clinical And Consulting PrepaidClinicalAndConsulting	517000	usd
CY2023Q2	PULM	Prepaid Software And Hosting Costs PrepaidSoftwareAndHostingCosts	119000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1638000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1068000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3078000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2983000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2799000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2748000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	279000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	235000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	64000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	81000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	746000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1130000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	287000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	475000	usd
CY2023Q2	PULM	Accrued Legal And Patent Current AccruedLegalAndPatentCurrent	74000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	94000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	33000	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1201000	usd
	us-gaap	Reimbursement From Limited Partnership Investment ReimbursementFromLimitedPartnershipInvestment	2300000	usd
CY2023Q2	us-gaap	Other Commitment OtherCommitment	4800000	usd
	PULM	Agreement Description AgreementDescription	Pursuant to the Amendment, the Company and Cipla will each initially be responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”). Upon the achievement of each development milestone set forth in the table below, Cipla will reimburse the Company an amount equal to 10% of the cumulative aggregate Direct Costs incurred (each reimbursement referred to as a “Holdback Payment”), potentially bringing the sharing of Direct Costs to a 50/50 basis. If a development milestone is not achieved, the respective Holdback Payment will continue to aggregate and be reimbursed by Cipla to the Company if the Company achieves the subsequent development milestone for that trial set forth in the table below. The Company will share all other development costs with Cipla that are not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis.
CY2023Q2	PULM	Transaction Costs TransactionCosts	22000000.0	usd
	PULM	Warrants Expired Shares WarrantsExpiredShares	123310	shares
	PULM	Warrants Expired Per Shares WarrantsExpiredPerShares	149.99	shares
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	255000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	277000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	551000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	558000	usd
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	4800000	usd
CY2023Q2	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	4300000	usd
CY2023Q2	us-gaap	Area Of Land AreaOfLand	22000
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	418000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	357000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	796000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	715000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	168000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	146000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	281000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	350000	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	586000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	503000	usd
	us-gaap	Lease Cost LeaseCost	1077000	usd
	us-gaap	Lease Cost LeaseCost	1065000	usd
CY2023Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	432000	usd
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	308000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	863000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	615000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y2M12D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0840	pure
CY2023Q2	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	359000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	359000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	358000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	358000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	358000	usd
	PULM	Payments To Leasehold Improvements PaymentsToLeaseholdImprovements	1700000	usd
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1554747000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1554747000	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1571368000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1571368000	shares

Files In Submission

Name	View Source	Status
0001493152-23-027468-index-headers.html	Edgar Link	pending
0001493152-23-027468-index.html	Edgar Link	pending
0001493152-23-027468.txt	Edgar Link	pending
0001493152-23-027468-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pulm-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pulm-20230630_cal.xml	Edgar Link	unprocessable
pulm-20230630_def.xml	Edgar Link	unprocessable
pulm-20230630_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pulm-20230630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PULM
Pulmatrix, Inc. Stock $pulm

2023 Q3 Form 10-Q Financial Statement

#000149315223027468 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM Pulmatrix, Inc. Stock $pulm

2023 Q3 Form 10-Q Financial Statement

#000149315223027468 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM
Pulmatrix, Inc. Stock $pulm